Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Cash & Equivalents data on record, last reported at $18.1 million in Q1 2025.

  • For Q1 2025, Cash & Equivalents rose 49.95% year-over-year to $18.1 million; the TTM value through Mar 2025 reached $18.1 million, up 49.95%, while the annual FY2025 figure was $18.1 million, 49.95% up from the prior year.
  • Cash & Equivalents reached $18.1 million in Q1 2025 per SXTC's latest filing, up from $12.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $18.1 million in Q1 2025 and bottomed at $45297.0 in Q1 2022.
  • Average Cash & Equivalents over 5 years is $12.2 million, with a median of $13.4 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: tumbled 99.66% in 2022, then skyrocketed 38243.55% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $13.4 million in 2021, then crashed by 99.66% to $45297.0 in 2022, then surged by 38243.55% to $17.4 million in 2023, then crashed by 30.5% to $12.1 million in 2024, then skyrocketed by 49.95% to $18.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $18.1 million in Q1 2025, $12.1 million in Q1 2024, and $17.4 million in Q1 2023.